Tilray Brands (TLRY) Receivables (2017 - 2026)
Tilray Brands' (TLRY) quarterly Receivables came in at $189.2 million in Q2 2026, up 55.71% YoY from $121.5 million in Q2 2025, and up 59.81% on a QoQ basis from $118.4 million in Q1 2026.
Tilray Brands (TLRY) Receivables (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Receivables data on file, last reported at $189.2 million in Q2 2026.
- Quarterly Receivables rose 55.71% year-over-year to $189.2 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $189.2 million (up 55.71% YoY) and the FY2026 annual result came in at $189.2 million, up 55.71% from the prior year.
- Receivables climbed to $189.2 million in Q2 2026, from $118.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $189.2 million in Q2 2026 to a low of $78.3 million in Q1 2023.
- A 5-year average of $103.7 million and a median of $98.3 million in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables retreated 16.54% — and 2026, when it jumped 55.71%.
- Tracing TLRY's Receivables over 5 years: stood at $89.7 million in 2022, then grew by 0.99% to $90.6 million in 2023, then grew by 24.44% to $112.7 million in 2024, then retreated by 3.25% to $109.1 million in 2025, then jumped by 73.44% to $189.2 million in 2026.
- The last three Receivables figures came in at $189.2 million (Q2 2026), $118.4 million (Q1 2026), and $109.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Tilray Brands | 512.61 Mn | 277.98 Mn | 90.52 Mn | 189.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 189.17 Mn |
| Feb 28, 2026 | 118.37 Mn |
| Nov 30, 2025 | 109.07 Mn |
| Aug 31, 2025 | 107.08 Mn |
| May 31, 2025 | 121.49 Mn |
| Nov 30, 2024 | 112.74 Mn |
| Aug 31, 2024 | 104.04 Mn |
| May 31, 2024 | 101.70 Mn |
| Feb 29, 2024 | 89.54 Mn |
| Nov 30, 2023 | 90.60 Mn |
| Aug 31, 2023 | 82.08 Mn |
| May 31, 2023 | 86.23 Mn |
| Feb 28, 2023 | 78.34 Mn |
| Nov 30, 2022 | 89.71 Mn |
| Aug 31, 2022 | 98.35 Mn |
| May 31, 2022 | 95.28 Mn |
| Feb 28, 2022 | 89.90 Mn |
| Nov 30, 2021 | 84.58 Mn |
| Aug 31, 2021 | 97.18 Mn |
| May 31, 2021 | 87.31 Mn |